Financial reports
10-K
2018 FY
Annual report
15 Mar 19
10-Q
2018 Q3
Quarterly report
7 Nov 18
10-Q
2018 Q2
Quarterly report
8 Aug 18
10-Q
2018 Q1
Quarterly report
10 May 18
10-K
2017 FY
Annual report
28 Mar 18
NT 10-K
Notice of late annual filing
16 Mar 18
NT 10-Q
Notice of late quarterly filing
13 Nov 17
NT 10-Q
Notice of late quarterly filing
10 Aug 17
NT 10-Q
Notice of late quarterly filing
11 May 17
10-K/A
2014 FY
Annual report (amended)
27 Mar 17
Current reports
8-K
Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
17 Apr 19
8-K
Entry into a Material Definitive Agreement
12 Mar 19
8-K
Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc
12 Mar 19
8-K
Departure of Directors or Certain Officers
26 Nov 18
8-K
Other Events
8 Nov 18
8-K
Osiris Therapeutics, Inc Reports Third Quarter 2018 Results
7 Nov 18
8-K
Other Events
17 Sep 18
8-K
Departure of Directors or Certain Officers
11 Sep 18
8-K
Departure of Directors or Certain Officers
10 Jul 18
8-K
Entry into a Material Definitive Agreement
2 Jul 18
Registration and prospectus
15-12B
Securities registration termination
29 Apr 19
25-NSE
Exchange delisting
17 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Apr 19
SC TO-T/A
Third party tender offer statement (amended)
17 Apr 19
SC 14D9/A
Tender offer solicitation (amended)
17 Apr 19
SC 14D9/A
Tender offer solicitation (amended)
16 Apr 19
Proxies
DEFA14A
Additional proxy soliciting materials
11 May 18
DEF 14A
Definitive proxy
11 May 18
PRE 14A
Preliminary proxy
23 Apr 18
DEF 14A
Definitive proxy
30 Apr 15
DEFA14A
Additional proxy soliciting materials
30 Apr 15
PRE 14A
Preliminary proxy
21 Apr 15
DEF 14A
Definitive proxy
28 Mar 14
DEFA14A
Additional proxy soliciting materials
28 Mar 14
DEF 14A
Definitive proxy
9 Apr 13
DEFA14A
Additional proxy soliciting materials
9 Apr 13
Other
CERT
Certification of approval for exchange listing
31 Jul 18
CT ORDER
Confidential treatment order
3 Sep 15
UPLOAD
Letter from SEC
5 Apr 11
CORRESP
Correspondence with SEC
21 Mar 11
CORRESP
Correspondence with SEC
24 Feb 11
UPLOAD
Letter from SEC
11 Feb 11
CORRESP
Correspondence with SEC
18 Jan 11
CORRESP
Correspondence with SEC
7 Jan 11
UPLOAD
Letter from SEC
16 Dec 10
CORRESP
Correspondence with SEC
16 Apr 10
Ownership
4
PETER FRIEDLI
17 Apr 19
4
Jason Keefer
17 Apr 19
4
Alla Danilkovitch
17 Apr 19
3
Samson Tom
29 Nov 18
3
Charles A. Reinhart III
17 Sep 18
3
VENTURETEC AG NEW
25 Jul 18
SC 13D/A
Osiris Therapeutics, Inc.
25 Jul 18
4
Change in insider ownership
25 Jul 18
4
Change in insider ownership
9 Jul 18
4
Jason Keefer
28 Jun 18